DailyDime

The highest-stakes call in a sale is not the price, it is which kind of buyer you hand the keys to.

The first time I watched a founder take the lower offer, the gap was eleven million dollars and the reason was one line in the LOI about who kept the customer relationships.

Global M&A announced value hit $2.8 trillion in the first half of 2026, up 48 percent year over year and the highest first half since records began in 1980. Deal count went the other way, falling 9 percent to roughly 24,000, a six-year low. Fewer companies are changing hands, and the ones that do are commanding more attention from more buyers.

That split matters for founders more than the headline. A thinner deal count with more capital chasing it means the average seller who runs a real process gets multiple bites at the same asset, often from buyers with completely different reasons for wanting it. One is buying your customers, your distribution, or your engineering team. The other is buying your cash flow and a plan to grow it for four to seven years before selling it again.

Those two motivations produce different prices, different structures, different post-close jobs for you, and different outcomes for your people. The right answer depends on what you want the day after closing, not on which spreadsheet produces the bigger number.

What Actually Separates a Strategic vs. Financial Buyer

A strategic buyer is an operating company. It underwrites your business as a piece of its own, so it can pay for synergy value that shows up on its P&L and nowhere on yours. A financial buyer, almost always a private equity firm, underwrites your business as a standalone asset it will lever, improve, and sell.

That single difference cascades through every term in the deal. The strategic is solving a business problem and will pay a premium when your company solves it faster than building the capability internally. The sponsor is solving a returns problem and will pay up only to the point where the model still clears its hurdle rate.

Strategics dominate where the synergy case is real and quantifiable. EY projected strategic deal volume to rise about 11 percent in 2026 while private equity deal volume stayed roughly flat, which tells you something about where the aggression is right now.

Financial buyers remain the deeper bench in the middle market by count. US middle market PE deal value reached $103.8 billion in the first quarter of 2026, up 10.7 percent year over year and the strongest start to a year since 2021. US private equity dry powder is sitting near $1 trillion, and most of that capital was raised in the 2022 to 2024 window, meaning the clocks on it are running.

What the Strategic Buyer Is Really Paying For

Strategics pay the highest headline number when they can point to a specific dollar of synergy. Cross-sell into their channel, a plant they can consolidate, a compliance function they already staff, a product gap that would cost them three years to build. When those numbers are defensible to their own board, the premium is real.

The tradeoff is that everything you built becomes an input to someone else’s system. Headcount overlap gets resolved in their favor. Your brand may survive as a product line or disappear into theirs. The team you spent a decade assembling reports into a structure you do not control.

Earnouts from strategics deserve particular caution. They are frequently tied to revenue retention or integration milestones that the buyer controls after closing. If they move your product onto their platform, reprice it, or reassign your account managers, the metric you are being measured on is no longer yours to influence. Anyone weighing this path should understand how earn-outs actually pay out and where sellers lose them before signing an LOI that defers a fifth of the price.

The upside is clean. Most strategic deals close mostly in cash, the transition service period runs six to nine months, and you are done. For a founder who has already hit the number that lets them walk away without doing this again, certainty has enormous value that no model captures.

What the Private Equity Buyer Is Really Paying For

A sponsor is buying a platform. They want predictable cash flow, a management team that stays, a fragmented market they can consolidate through add-ons, and enough operational slack that they can grow EBITDA without a miracle.

They also want you invested alongside them. Rollover equity appears in roughly two thirds of sponsor transactions, typically at 10 to 30 percent, and it serves three purposes at once. It signals your confidence, it keeps you motivated after the check clears, and it reduces the sponsor’s equity outlay on the deal.

The structural cost is leverage. The business you ran with a clean balance sheet will carry real debt the day after closing, which changes how you make decisions about hiring, capex, and pricing. Founders who have never operated a levered company underestimate how much that constrains them. The mechanics of choosing between debt and equity capital are worth understanding before you find yourself living inside someone else’s capital structure.

The governance cost is control. You become a minority partner with a board, a monthly reporting package, and an exit timeline set by someone else. If the sponsor decides to sell in year four because their fund needs a DPI print, you sell in year four.

A $100 Million Exit, Run Two Ways

Numbers make this concrete. The baseline for both scenarios is identical: $100 million enterprise value, cash-free and debt-free, on $10 million of EBITDA at a 10x multiple, with $15 million of equity capital previously invested by the founder group.

The strategic pays $87 million in cash at closing, roughly $8.7 million of which sits in escrow for 12 to 18 months, and defers $13 million into an earnout tied to revenue retention and integration milestones over 24 months. Cash at close alone is 5.8x the $15 million invested. The earnout adds another 0.9x if it pays in full, which is the part nobody should count on. Your role is a six to nine month transition, then out.

The sponsor funds the same $100 million from four sources: $50 million of senior and unitranche debt at 5.0x EBITDA, a $36 million equity check, $12 million of rolled equity from you, and a $2 million subordinated seller note. Cash to the founder group at closing is $86 million, the debt plus the sponsor’s check. That is 5.7x on the $15 million invested, within a rounding error of what the strategic paid. The rolled $12 million buys 25 percent of a $48 million post-close equity base.

Now the second bite. Assume the sponsor holds five years, grows EBITDA from $10 million to $16 million through organic improvement and two add-ons, exits at the same 10x for a $160 million enterprise value, and pays debt down from $50 million to $25 million. Equity value at exit is $135 million. A 10 percent management option pool dilutes your stake from 25 percent to 22.5 percent, producing roughly $30 million and a full-cycle total near $118 million. The downside case is the one that never makes it into a banker’s deck. If EBITDA only reaches $12 million and multiples compress to 8x, enterprise value is $96 million, debt sits at $35 million, and the equity is worth $61 million. Your 22.5 percent returns about $14 million, and the full-cycle total lands near $102 million. Five extra years of risk and reporting for roughly what the strategic paid in cash on day one.

These figures are stylized, though the shape holds for a clean middle-market deal. Actual percentages move with leverage availability, growth rate, competitive tension, and how badly each buyer wants the asset. Median private equity entry multiples reached 11.9x EV/EBITDA in the first quarter of 2026, up from 11.5x in 2025, so the leverage math above is on the conservative side of what sponsors are underwriting today.

The line that surprises most founders is cash at closing. At 2026 leverage levels, a sponsor writing a levered check often lands within a point or two of what a strategic pays in cash. The real difference is not the money on day one, it is the five years of risk attached to the back half of the outcome.

The Rollover Denominator Trap

Here is where founders get hurt, and it is not the percentage. It is what the percentage is measured against.

“We would like you to roll 25 percent” can mean 25 percent of your proceeds or 25 percent of the post-close equity. Those are wildly different deals. In the example above, 25 percent of post-close equity cost $12 million. Rolling 25 percent of a $100 million consideration would have cost $25 million, cut cash at close from $86 million to $73 million, and bought roughly half the company. Settle the denominator in the first conversation, in writing.

The security type matters even more than the size. A 25 percent rollover into common stock sitting behind a sponsor’s 2x participating preferred can be worth less at exit than a 12 percent rollover into the same class the sponsor holds. Ask what class you are receiving, whether it is pari passu with the sponsor, what the preferred return accrues at, and how add-on acquisitions dilute you.

Rolled equity is also illiquid for the entire hold, with no secondary market for lower middle market platform stock. Model it as risk capital with execution risk attached, not as a deferred cash equivalent.

Questions to Answer Before You Pick a Lane

The decision gets easier when you answer these honestly, before offers arrive and anchor your thinking.

• Do you want maximum cash today and a clean break, or are you willing to leave certainty on the table for a shot at a larger second exit?
• Is there a strategic buyer with real, quantifiable synergies, or are you mostly looking at financial buyers underwriting standalone performance?
• How much does cultural continuity for your team actually matter to you, measured in dollars you would give up for it?
• Have you ever run a business carrying five turns of debt, and do you want to?
• Can you take direction from a board for three to five years after a decade of answering to nobody?

Most founders run a dual-track process precisely because these answers only sharpen once real paper is on the table. Running both tracks also creates the competitive tension that improves whichever offer wins.

Size shapes your options here too. The larger you get, the smaller your buyer universe becomes, which is one reason bigger companies are often harder to sell than the founders of those companies expect.

What Both Buyers Will Test in Diligence

Preparation moves the number regardless of who wins, and both buyer types converge on the same short list of things that kill or reprice deals.

Quality of earnings comes first. Every add-back you claim will be challenged by an accounting firm working for the buyer, and the ones that survive are the ones documented contemporaneously rather than reconstructed during diligence. Knowing which EBITDA add-backs buyers actually accept before you go to market is worth more than any pitch deck.

Customer concentration is the second. A single account above 20 percent of revenue reprices the deal or moves consideration into an earnout, no matter which buyer you choose. Management depth is the third, and it cuts differently by buyer: a strategic may see a thin bench as a synergy opportunity, while a sponsor sees it as the reason the platform stalls in year two.

Structure gets negotiated differently by each side as well. Working capital pegs, debt-like items, and representations and warranties insurance all shift depending on whether the buyer is folding you into an existing entity or standing you up as a platform. The choice between an asset purchase and an equity purchase has tax consequences worth real money, and buyers have a strong preference that they will not volunteer.

Valuation expectations are the last piece. Anchoring to a multiple you read about is the fastest way to blow up a process, so calibrate against what businesses of your size and sector actually trade for rather than against the outlier deal your industry association publicized.

Where to Start

If a process is somewhere on your horizon, the preparation is identical for both paths and pays for itself either way: normalized earnings you can defend line by line, a named list of strategic acquirers with a specific synergy thesis for each, and an honest view of what a sponsor would underwrite on your numbers today.

Founders who do that work negotiate from a different position, and they tend to be happier with the outcome regardless of which buyer signs. It also helps to understand the other side of the table, since many of the sponsors and independent buyers competing for your business are running the same acquisition playbook you could run yourself.